Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 2,212 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blinded (placebo) Clear all
Completed Phase 2 Interventional

Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer

NCT01792050
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Docetaxel, Placebo, Indoximod, Paclitaxel
Drug · Other
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
28
States / cities
Gainesville, Florida • Tampa, Florida • Titusville, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 21, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation

NCT01225211
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Lumacaftor, Ivacaftor, Lumacaftor Placebo, Ivacaftor Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
38
States / cities
Birmingham, Alabama • Anchorage, Alaska • La Jolla, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Oct 21, 2026, 2:05 PM EDT
Completed Phase 4 Interventional

Biomarkers of Antidepressant Treatment in Adolescents With Major Depression (The Adolescents MDD Study)

NCT01185977
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Fluoxetine, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
14 Years to 18 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 3, 2014 · Synced Oct 21, 2026, 2:05 PM EDT
Completed Phase 3 Interventional Results available

Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)

NCT02091375
View directory record Official record
Conditions
Epilepsy, Dravet Syndrome
Interventions
GWP42003-P 20 mg/kg/day Dose, Placebo control
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
13
States / cities
Miami, Florida • Orlando, Florida • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 21, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Intranasal Capsaicin Treatment for Non-Allergic Irritant Rhinitis

NCT02493257
View directory record Official record
Conditions
Nonallergic Irritant Rhinitis
Interventions
Capsaicin, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Oct 21, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease

NCT01024036
View directory record Official record
Conditions
Multicentric Castleman's Disease
Interventions
Siltuximab, Placebo, Best Supportive Care (BSC)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
11
States / cities
Little Rock, Arkansas • Los Angeles, California • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Oct 21, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending and Multiple Doses of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Healthy Japanese Participants

NCT04302064
View directory record Official record
Conditions
Healthy Participants
Interventions
Eplontersen, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
20 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 21, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A118G SNP and OPRM1 Gene Opioid-Mediated Effects in Humans

NCT02360371
View directory record Official record
Conditions
Opioid Sensitivity, Individual Difference, Abuse Opioids
Interventions
Within-subject test of blinded study medication
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 21, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.

NCT02963909
View directory record Official record
Conditions
Zika Virus Infection
Interventions
IXIARO, Placebo, YF Vax 17D Strain, Zika Virus Purified Inactivated Vaccine (ZPIV)
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Oct 21, 2026, 2:05 PM EDT
Completed Early Phase 1 Interventional

Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash

NCT03471364
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Ketoconazole, Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
6
States / cities
Danville, Illinois • Urbana, Illinois • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 21, 2026, 2:05 PM EDT
Not yet recruiting Phase 2 Interventional

Naloxone for Opioid Associated Out of Hospital Cardiac Arrest

NCT06251609
View directory record Official record
Conditions
Heart Arrest, Out-Of-Hospital, Opioid Overdose, Naloxone
Interventions
Naloxone 2 MG, Saline 2ml
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 21, 2026, 2:05 PM EDT
Completed Phase 4 Interventional Results available

Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response (NEMO)

NCT03128021
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram Pill, Placebo, Levomilnacipran Pill
Drug · Other
Lead sponsor
Howard Aizenstein
Other
Eligibility
60 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 21, 2026, 2:05 PM EDT
Completed Phase 2 Interventional

Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection

NCT01435044
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Sofosbuvir, GS-0938, RBV, Placebo to match sofosbuvir, Placebo to match GS-0938
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
42
States / cities
Montgomery, Alabama • Bakersfield, California • Coronado, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 21, 2026, 2:05 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

NCT01472198
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Simtuzumab, Gemcitabine, Placebo to match simtuzumab
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
44
States / cities
Birmingham, Alabama • Mobile, Alabama • Alhambra, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Oct 21, 2026, 2:05 PM EDT
Completed Phase 3 Interventional Results available

Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

NCT01690299
View directory record Official record
Conditions
Psoriasis, Psoriatic Arthritis
Interventions
Apremilast, Etanercept, Placebo tablet, Placebo injection
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
31
States / cities
Phoenix, Arizona • Bakersfield, California • Irvine, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 21, 2026, 2:05 PM EDT
Completed Phase 2 Interventional

A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects

NCT00112021
View directory record Official record
Conditions
Obesity
Interventions
pramlintide acetate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
21
States / cities
Chula Vista, California • San Diego, California • Walnut Creek, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2015 · Synced Oct 21, 2026, 2:05 PM EDT
Terminated Phase 2 Interventional Results available

Injecting Botulinum Toxin A Underneath the Skin to Treat Spinal Cord Pain in Patients With Spinal Cord Injury

NCT02736890
View directory record Official record
Conditions
Neuropathic Back Pain, Spinal Cord Injury
Interventions
Botulinum Toxin A, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Oct 21, 2026, 2:05 PM EDT
Terminated Phase 2 Interventional Results available

A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation

NCT02156076
View directory record Official record
Conditions
Paroxysmal Atrial Fibrillation
Interventions
BMS-919373, Placebo (Matching with BMS-919373)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
20
States / cities
Anaheim, California • Costa Mesa, California • Long Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 21, 2026, 2:05 PM EDT
Not yet recruiting Phase 1 Interventional

A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS).

NCT07883590
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Cytochrome P-450 Enzyme System
Interventions
LY3873862, CYP450 Drug Cocktail, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
San Francisco, California • Aurora, Colorado • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 2:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Radicle Clarity: A Study of Health and Wellness Products on Mental Clarity and Health Outcomes

NCT05652725
View directory record Official record
Conditions
Cognitive Function
Interventions
Clarity Active Study Product 1.1 Usage, Clarity Active Study Product 2.1 Usage, Clarity Active Study Product 3.1 Usage, Clarity Active Study Product 4.1 Usage, Clarity Active Study Product 4.2 Usage, Clarity Active Study Product 4.3 Usage, Placebo Control Form 1, Placebo Control Form 2, Placebo Control Form 3, Placebo Control Form 4, Placebo Control Form 5, Clarity Active Study Product 5.1 Usage, Clarity Active Study Product 5.2 Usage
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 105 Years
Enrollment
4,826 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 21, 2026, 2:05 PM EDT
Recruiting Phase 2 Interventional

Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

NCT06511908
View directory record Official record
Conditions
Suicide, Depressive Disorder, Treatment-Resistant, Ketamine, Molecular Mechanisms of Pharmacological Action, Neurotransmitter Agents, Excitatory Amino Acid Agents, Physiological Effects of Drugs, Depressive Disorder, Major, Depressive Disorder, Depression, Mental Disorders, Mood Disorders, Behavioral Symptoms
Interventions
(2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg), Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 2:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus

NCT01915849
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
LIK066, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2015 · Synced Oct 21, 2026, 2:05 PM EDT
Active, not recruiting Not applicable Interventional

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

NCT02194738
View directory record Official record
Conditions
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Carboplatin, Cisplatin, Clinical Observation, Computed Tomography, Crizotinib, Cytology Specimen Collection Procedure, Echocardiography Test, Erlotinib, Gemcitabine Hydrochloride, Nivolumab, Paclitaxel, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Placebo Administration, Positron Emission Tomography
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
7,458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1655
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 1013 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 21, 2026, 2:05 PM EDT
Terminated Phase 4 Interventional Results available

Dexmedetomidine (Precedex®) for Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD)

NCT01362205
View directory record Official record
Conditions
Alcohol Withdrawal Delirium, Alcohol Withdrawal Associated Autonomic Hyperactivity, Alcohol Withdrawal Hallucinosis, Alcohol Withdrawal-Induced Delirium Tremens
Interventions
Dexmedetomidine, Placebos
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 89 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
7
States / cities
Colorado Springs, Colorado • Denver, Colorado • Lakewood, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 21, 2026, 2:05 PM EDT